Logo

BMS Failed to Meet its Primary Endpoint in P-III (CheckMate -914) Trial for Opdivo (nivolumab) + Yervoy (ipilimumab) as Adjuvant Treatment of Localized Renal Cell Carcinoma

Share this

BMS Failed to Meet its Primary Endpoint in P-III (CheckMate -914) Trial for Opdivo (nivolumab) + Yervoy (ipilimumab) as Adjuvant Treatment of Localized Renal Cell Carcinoma

Shots:

  • Part A of the P-III (CheckMate -914) trial evaluating Opdivo + Yervoy in patients with localized RCC who have undergone full or partial removal of the kidney & are at mod. or high risk of relapse
  • The trial failed to meet its 1EPs of DFS as assessed by BICR & the safety profile was consistent with prior reported studies of the Opdivo + Yervoy in solid tumors. The therapy demonstrated clinical benefits across multiple RCC patient populations incl. Opdivo + Yervoy for untreated, intermediate & poor-risk RCC & for advanced RCC while Opdivo for 2L treatment of advanced or metastatic RCC
  • Opdivo or Opdivo + Yervoy is also being studied in combination with novel agents targeting alternative immunomodulatory molecules & pathways for RCC

Ref: Bussinesswire | Image: BMS

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions